ArticleMovement disorders : official journal of the Movement Disorder Society2020
SARS-CoV-2 as a Potential Trigger of Neurodegenerative Diseases.
Article in Movement disorders : official journal of the Movement Disorder Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Golgi Fragmentation as a Potential Link Between SARS-CoV-2 Infection and Alzheimer's Disease: Mechanisms and Implications for Neurodegeneration in Long COVID.Sub-cellular biochemistry · 2026Review
- SARS-CoV-2 and Brain Health: New Challenges in the Era of the Pandemic.Microorganisms · 2023Review
- Examining Association of Personality Characteristics and Neuropsychiatric Symptoms in Post-COVID Syndrome.Brain sciences · 2022Article
- Functional connectivity underlying cognitive and psychiatric symptoms in post-COVID-19 syndrome: is anosognosia a key determinant?Brain communications · 2022Article
- Editorial: COVID-19 in CNS and PNS: Basic and Clinical Focus on the Mechanisms of Infection and New Tools for the Therapeutic Approach.Frontiers in neurology · 2022Article
- Experimental Models of SARS-COV-2 Infection in the Central Nervous System.Journal of central nervous system disease · 2022Review
- A Review on SARS-CoV-2-Induced Neuroinflammation, Neurodevelopmental Complications, and Recent Updates on the Vaccine Development.Molecular neurobiology · 2021Review
- Nanobased Platforms for Diagnosis and Treatment of COVID-19: From Benchtop to Bedside.ACS biomaterials science & engineering · 2021Review
- The Immunopathogenesis of Neuroinvasive Lesions of SARS-CoV-2 Infection in COVID-19 Patients.Frontiers in neurology · 2021Review
- Microglial Implications in SARS-CoV-2 Infection and COVID-19: Lessons From Viral RNA Neurotropism and Possible Relevance to Parkinson's Disease.Frontiers in cellular neuroscience · 2021Review
- "Brain Fog" by COVID-19 or Alzheimer's Disease? A Case Report.Frontiers in psychology · 2021Article
- Reply to: SARS-CoV-2 as a Potential Trigger of Neurodegenerative Diseases.Movement disorders : official journal of the Movement Disorder Society · 2020Article
- Progress in Research on SARS-CoV-2 Infection Causing Neurological Diseases and Its Infection Mechanism.Frontiers in neurology · 2020Review
- Management of a Parkinson's disease patient with severe COVID-19 pneumonia.Therapeutic advances in chronic disease · 2020Article
- Experimental Models for the Study of Central Nervous System Infection by SARS-CoV-2.Frontiers in immunologyReview
Corrections and comments
- Commented on by
- Comment on
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.